Rhode Island Clinical Trials Report — June 2026

For Rhode Islanders considering participation in clinical research, June 2026 presents a crucial window of opportunity, particularly for studies nearing their enrollment deadlines. Across the state, 36 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 6 studies that are actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various neurological, respiratory, and behavioral health challenges are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Healthy volunteers (2 trials)
• Aggression in childhood
• Asthma in children
• Alcohol use disorder (AUD)
• Alzheimer's disease
• Alzheimer disease
• Agitation, psychomotor
• Astrocytoma
• Astrocytoma, IDH-mutant
• Autoimmune diseases

New Horizons in Rhode Island Research: Major Trials Launch

This June, Rhode Island welcomes 6 new clinical trials, matching the number that opened in May 2026. These new studies include significant Phase 2 and 3 drug trials from major pharmaceutical companies, offering participants access to cutting-edge treatments for widespread health challenges like obesity and type 2 diabetes, as well as an important device registry study.

• AstraZeneca is sponsoring NCT07662135, a Phase 3 study investigating "The Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin." This substantial trial aims to enroll 900 participants to evaluate a new treatment for type 2 diabetes in individuals also experiencing impaired kidney function.
• For those living with obesity, Novo Nordisk A/S is leading NCT07639021, a Phase 2 research study comparing "Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity." This trial plans for 230 participants to assess the safety and effectiveness of a new compound for weight management.
• Stryker Orthopaedics is sponsoring NCT07647354, the "Mako-MORE Registry." This is a prospective, post-market, multi-center, registry-based observational study designed to collect real-world clinical data on patients undergoing joint arthroplasty with Stryker implants, with or without the use of the Mako Robotic-Arm Assisted System.

Beyond these notable industry-sponsored studies, other new research initiatives are also underway. Brown University is sponsoring 2 new trials, and Pro-Change Behavior Systems is sponsoring 1, contributing to a mix of academic and industry-led research efforts in the state.

Expanding Opportunities Across Conditions and Interventions

The 6 new trials opening this month in Rhode Island cover a diverse range of health conditions. The most common conditions addressed by these new studies include:

• Alcohol drinking
• Appendiceal adenocarcinoma
• Arthropathy of hip
• Arthropathy of knee
• Belonging
• Colorectal adenocarcinoma
• LGBTQ
• Malignant ascites
• Mental health
• Obesity

In terms of intervention types, drug trials lead the way, accounting for 3 of the new studies. Behavioral interventions are also represented with 2 new trials, alongside 1 device study.

Rhode Island's Research Landscape: Where to Find Trials

Rhode Island's clinical research landscape is active, with a total of 492 clinical trials currently recruiting across 14 cities and 197 research sites statewide. This month, new research initiatives have opened in several communities, expanding access beyond the capital:

• Providence (2 new trials)
• Cumberland (1 new trial)
• East Providence (1 new trial)
• Narragansett (1 new trial)
• Wakefield (1 new trial)

While Providence remains a central hub for clinical investigations, the distribution of new trials across these cities ensures that residents in various regions of Rhode Island have access to cutting-edge research opportunities.

Healthy Volunteers and Inclusive Participation

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 6 new trials launched this month, 2 are actively seeking healthy volunteers. Statewide, a total of 55 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Rhode Island are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 5 include older adults as participants, ensuring that research benefits this demographic. No new trials this month are exclusively for children, females, or males. Academic institutions, such as Brown University, continue to play a vital role in the state's research ecosystem, sponsoring 2 of the new trials. Industry sponsors like AstraZeneca, Novo Nordisk A/S, and Stryker Orthopaedics are also driving significant research efforts, sponsoring 3 new trials this month.

As we move through June, the focus will remain on the ongoing enrollment in these significant Phase 2 and 3 trials, the Mako-MORE Registry, and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Rhode Island.